Page 13 of 32 · 745 questions tagged clinical-trials.
The clinician who ordered the panel was not concerned; I would still like to understand it. I would like help reading this properly rather than being told what…
Setup, so nobody has to ask: hair thinning · a GLP-1 receptor agonist · STEP 3. I would like help reading this properly rather than being told what conclusion to…
Concretely: STEP 2 · dizziness · 1 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…
Setup, so nobody has to ask: SURPASS-2 · tirzepatide. I have read the primary source rather than the summary, which has left me with more questions. I understand the…
I have the full paper rather than the abstract, and the supplementary appendix. I understand the observation; what I do not understand is the mechanism behind it. I…
Details up front: mazdutide · tirzepatide. I have used one of these for a while and I am considering switching, which requires a reason. What I care about is…
What I am working with: FLOW · dizziness · 1 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the…
Numbers first: ATTAIN-1 · hair thinning. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
Concretely: SUSTAIN-6 · 1 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which I…
What I am working with: SELECT · semaglutide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
What I have: STEP 2 · nausea · 1 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
Numbers first: SURMOUNT-4 · tirzepatide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
For reference: retatrutide · survodutide. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain either…
Orforglipron is described as a non-peptide oral GLP-1 receptor agonist, which I take to mean it is a conventional small molecule rather than a peptide with a delivery…
What I am working with: SELECT · 1 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including the…
Numbers first: STEP 4 · semaglutide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence exists…
Stated plainly: STEP 1 · vomiting · 2 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including…
Details up front: vomiting · tirzepatide · SURPASS-3. This is presented as though it settles something, and I am not convinced it does. I have two documents that…
I have three data points across nine months, which I hope is enough to see a trend. I would rather understand the derivation than memorise the outcome. Two people I…
I have looked for a randomised comparison of dosing frequency within a single molecule in this class and cannot find one. Every phase 3 trial I can find fixed the…
What I have: mazdutide · 30 °C. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am interested in…
Stated plainly: dulaglutide · room temperature. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all…
The specifics, since they change the answer: SURPASS-2 · hair thinning · 15 mg. I want to understand what this actually establishes, as opposed to what it is being…
The particulars: fatigue · oral semaglutide · PIONEER-4. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern…